» Articles » PMID: 24833794

α5β1 Integrin Signaling Mediates Oxidized Low-density Lipoprotein-induced Inflammation and Early Atherosclerosis

Overview
Date 2014 May 17
PMID 24833794
Citations 62
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Endothelial cell activation drives early atherosclerotic plaque formation. Both fibronectin deposition and accumulation of oxidized low-density lipoprotein (oxLDL) occur early during atherogenesis, and both are implicated in enhanced endothelial cell activation. However, interplay between these responses has not been established. The objective of our study was to determine whether endothelial matrix composition modulates the inflammatory properties of oxLDL.

Approach And Results: We now show that oxLDL-induced nuclear factor-κB activation, proinflammatory gene expression, and monocyte binding are significantly enhanced when endothelial cells are attached to fibronectin compared with basement membrane proteins. This enhanced response does not result from altered oxLDL receptor expression, oxLDL uptake, or reactive oxygen species production, but results from oxLDL-induced activation of the fibronectin-binding integrin α5β1. Preventing α5β1 signaling (blocking antibodies, knockout cells) inhibits oxLDL-induced nuclear factor-κB activation and vascular cell adhesion molecule-1 expression. Furthermore, oxLDL drives α5β1-dependent integrin signaling through the focal adhesion kinase pathway, and focal adhesion kinase inhibition (PF-573228, small interfering RNA) blunts oxLDL-induced nuclear factor-κB activation, vascular cell adhesion molecule-1 expression, and monocyte adhesion. Last, treatment with the α5β1 signaling inhibitor, ATN-161, significantly blunts atherosclerotic plaque development in apolipoprotein E-deficient mice, characterized by reduced vascular cell adhesion molecule-1 expression and macrophage accumulation without affecting fibrous cap size.

Conclusions: Our data suggest that α5β1-mediated cross-talk between fibronectin and oxLDL regulates inflammation in early atherogenesis and that therapeutics that inhibit α5 integrins may reduce inflammation without adversely affecting plaque structure.

Citing Articles

Fibronectin Mediates Endothelial-to-Mesenchymal Transition in Retina Angiogenesis.

Liu D, Meng Z, Jin C, Chen F, Pu L, Wu Z Invest Ophthalmol Vis Sci. 2025; 66(3):10.

PMID: 40042877 PMC: 11892531. DOI: 10.1167/iovs.66.3.10.


Free radicals and their impact on health and antioxidant defenses: a review.

Chandimali N, Bak S, Park E, Lim H, Won Y, Kim E Cell Death Discov. 2025; 11(1):19.

PMID: 39856066 PMC: 11760946. DOI: 10.1038/s41420-024-02278-8.


Vascular Extracellular Matrix in Atherosclerosis.

Di Nubila A, Dilella G, Simone R, Barbieri S Int J Mol Sci. 2024; 25(22).

PMID: 39596083 PMC: 11594217. DOI: 10.3390/ijms252212017.


Electrospun Fiber Surface Roughness Modulates Human Monocyte-Derived Macrophage Phenotype.

Alemifar A, Burnette K, Jandres B, Hurt S, Tse H, Robinson J bioRxiv. 2024; .

PMID: 39282362 PMC: 11398424. DOI: 10.1101/2024.08.30.610568.


Different roles of endothelial cell-derived fibronectin and plasma fibronectin in endothelial dysfunction.

Luo X, Jian W Turk J Med Sci. 2024; 53(6):1667-1677.

PMID: 38813506 PMC: 10760598. DOI: 10.55730/1300-0144.5735.


References
1.
Rosenfeld M, Palinski W, Yla-Herttuala S, Butler S, Witztum J . Distribution of oxidation specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis. 1990; 10(3):336-49. DOI: 10.1161/01.atv.10.3.336. View

2.
Livant D, Brabec R, Pienta K, Allen D, Kurachi K, Markwart S . Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma. Cancer Res. 2000; 60(2):309-20. View

3.
White S, Sala-Newby G, Newby A . Overexpression of scavenger receptor LOX-1 in endothelial cells promotes atherogenesis in the ApoE(-/-) mouse model. Cardiovasc Pathol. 2010; 20(6):369-73. PMC: 3206208. DOI: 10.1016/j.carpath.2010.08.007. View

4.
Abshire M, Thomas K, Owen K, Bouton A . Macrophage motility requires distinct α5β1/FAK and α4β1/paxillin signaling events. J Leukoc Biol. 2010; 89(2):251-7. PMC: 3024900. DOI: 10.1189/jlb.0710395. View

5.
Amberger A, Maczek C, Jurgens G, Michaelis D, Schett G, Trieb K . Co-expression of ICAM-1, VCAM-1, ELAM-1 and Hsp60 in human arterial and venous endothelial cells in response to cytokines and oxidized low-density lipoproteins. Cell Stress Chaperones. 1997; 2(2):94-103. PMC: 312986. DOI: 10.1379/1466-1268(1997)002<0094:ceoive>2.3.co;2. View